Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

HC Wainwright raised their target price on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B.

Madrigal Pharmaceuticals (MDGL) announced it has appointed Jacqualyn Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring ...

Madrigal Pharmaceuticals has a 12 month low of $189.00 and a 12 month high of $377.46. Madrigal Pharmaceuticals ( NASDAQ:MDGL – Get Free Report ) last posted its earnings results on Wednesday ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash ...